Women at risk of similar cancer should be managed similar. It is therefore rational to provide the same care for fellow women at risk of similar cancer. We recognize that women at different ages may have compromised the benefits and harms of screening. These differences are handled by the development of specific screening recommendations to age. 36 we included studies that used either method of cytology. We found no data to suggest a need to analyze the data from studies using liquid-based cytology separately from those using conventional cytology.
Performance characteristics vary between these HPV tests, and comparability can not be met. Therefore, we recommend not using LDTS for screening of cervical cancer. HPV testing should be used for their packaging label. interlaboratory tests or competence to ensure quality results in laboratories should be established50 all well validated through research, interlaboratory comparability additional studies of HPV testing in the clinical laboratory would help. An initial literature search for relevant terms in all the working groups was made, and abstracts were reviewed by members of the dataset.
Products meeting the initial inclusion criteria were retrieved and distributed to each working group, as applicable. The members of the working groups then discussed each item to determine if data were available on the critical or important results. The quality system does not specifically address modeling studies, which were often the only evidence available for comparing alternatives, especially different screening intervals. Members of the steering group and the data committee and other working groups, reviewed the recommendations and the corresponding justification and provided comments. The revised draft recommendations and the rationale was posted on the website of ASCCP public consultation from 19 October 2011 to November 9, 2011. Public comments were distributed to each workgroup, and revisions were made to resolve or clarify the issues raised.
A symposium was held November 17 to 18, 2011, to consider, revise as necessary, and vote on final recommendations. Each working group presented its assessment of recommendations on evidence and projects. After the presentation, there was an open discussion followed by a vote on the recommendations, including both the wording of the recommendation and the strength of the recommendation. These guidelines were developed to address the Pap test in the general population. These guidelines do not address the people, special high risk may need more intensive or alternative screening.
The following recommendations are based on a review and evaluation of the published literature reviewed by peers available at the time of the conference. It is expected that they will be reviewed on an ongoing basis and revised when new information becomes available about the impact of alternative strategies on the balance of advantages and disadvantages of screening for cervical cancer. The following recommendation has been endorsed by several organizations that participated in this meeting. The Pap test should begin at the age of 21. Women aged under 21 should not be considered irrespective of the age of sexual initiation or other risk factors. Cervical cancer is rare in adolescents and young women58 and can be prevented by cytology screening59 the incidence of cervical cancer screening in this age group has not changed with the increased coverage screening over the past four teenagers decades58 screening leads to unnecessary evaluation and treatment of potentially precancerous cervical lesions that have a high probability of regressing spontaneously and are on average many years to have a significant potential to become a cancer invasive.
This overtreatment, and after an increased risk of reproductive problems, a net harm33. cancer prevention programs cervical teenagers should focus on universal vaccination against HPV, which is safe, highly effective, and, when used in adolescents before they become sexually active, very effective and economical effective60.
HPV Causes Cervical Cancer | Treatment Of Cancer Caused By HPV